

CURRICULUM VITAE
BARRY MICHAEL BERNSTEIN, M.D.

Office Address: AbbVie
Dept R48U Bldg AP30-3
1 North Waukegan Road
North Chicago, 60064
(847) 938-0013

Current Title Vice President
Infectious Disease Development
AbbVie

Undergraduate Education: University of Wisconsin-Milwaukee, 1970-71
Northwestern University, 1971-1973

Postgraduate Training and Fellowship Appointments:

1973-77 MD, Duke University School of Medicine, Durham, NC
1977-78 Intern, Internal Medicine, Ohio State University Hospital, Columbus, OH
1978-79 Resident, Internal Medicine, Ohio State University Hospital, Columbus, OH
1979-81 Fellowship, Infectious Disease, Ohio State University Hospital, Columbus, OH
1981-82 Resident, University of Arizona Hospital, Tempe, AZ

Faculty Appointments:

1989 Assistant Professor, Division of Infectious Disease, Medical College of WI
1994 - 1998 Associate Professor of Clinical Medicine, Division of Infectious Diseases,
Medical College of Wisconsin

1995-1998 Hospital Epidemiologist, Froedtert Memorial Lutheran Hospital
1995-1998 Pharmaceutical and Therapeutics Committees, Froedtert Memorial Lutheran
Hospital
1995-1998 Section Head, Division of Infectious Diseases, Froedtert Memorial Lutheran
Hospital

Professional Experience

1989. 1982-1989 Private Practice Milwaukee Medical Clinic (infectious disease)
1998. 1989-1998 Faculty Medical College of Wisconsin (Division of Infectious
Disease)
Major Responsibilities:
Director, AIDS Program, Medical College of Wisconsin
Medical Director, Infectious Disease Clinic, Froedtert Memorial
Lutheran Hospital
Antibiotic Utilization Review Committee, Froedtert Memorial Lutheran
Hospital
Director of Medical Education, Midwest AIDS Training and Education

Center (MATEC) - Wisconsin
Chairman, Infection Control Committee Froedtert Memorial Lutheran
Hospital
Epidemiologist, Froedtert Memorial Lutheran Hospital
Pharmaceutical and Therapeutics Committees, Froedtert Memorial
Lutheran Hospital
Section Head, Division of Infectious Diseases, Froedtert Memorial
Lutheran Hospital

1998-2001 Associate Medical Director, Abbott Laboratories Antiviral Venture
2001-2002 Medical Director, Abbott Laboratories Antiviral Venture
Major Responsibilities:
Design, oversight and analysis of phase I – IV clinical trials
Primary safety officer for multiple clinical trials
Support NDA activities including medical authorship of clinical study
reports and other components of the NDA submission
Support development and implementation of commercialization
strategies post approval, worldwide

2002-2005 Director, Abbott Laboratories Clinical Safety Evaluations Group
2003-2005 Acting Director, Abbott Laboratories Postmarketing Safety Evaluations Group
Major Responsibilities:
Responsible for overseeing development, interpretation and compliance
with SOPs and compliance with worldwide pharmacovigilance
regulations pertaining to processing and reporting of all clinical study
and postmarketing adverse event reports.
Responsible for the strategic medical assessment of all Abbott products
to proactively identify safety signals and recommend appropriate actions,
including medical analyses for Periodic Safety Update Reports.
Responsible for management of Clinical and Postmarketing Safety staff
including 13 physicians, medical writer and administrative staff

2005-2007 Senior Medical Director, Abbott Laboratories Antiviral Clinical Project Team
Major Responsibilities:
Design, oversight and analysis of phase I – IV clinical trials
Primary safety officer for multiple clinical trials
Labeling updates
Support development and implementation of commercialization
strategies, worldwide

2007-2012 Global Project Head/Project Director Antiviral Global Project Team
Major Responsibilities:
Develop and implement life cycle management strategies for approved
antiviral agents (Kaletra and Norvir), including new formulations, doses,

and clinical utility. (to mid-2009)

Management of Antiviral Medical Affairs (to mid-2009)

Oversight of Hepatitis C clinical development program including multiple IND submissions, first-in-human trials, proof of concept trials, and mid-late stage development strategies.

Assessment of inlicensing and other business development opportunities in Hepatitis C

Management of Senior Medical Directors/Medical/Scientific Directors in Hepatitis C therapeutic area

2012-present

Vice President, Infectious Disease Development

Responsible for all development activities in the HCV, HIV and RSV programs, including submission and approval of the interferon-free HCV therapies in the US, EU and Asia

Development of Innovation Plan for Hepatology Franchise, with assessment of multiple business development opportunities in hepatology

Specialty Certification:

1982 American Board of Internal Medicine

Licensure:

1977 Ohio
1981 Arizona
1982 Wisconsin

Memberships in Professional and Honorary Societies:

1992-93 Physicians Associated with AIDS Care (PAAC)
1992-1998 Society for Hospital Epidemiology (SHEA)
1997-2000 Infectious Disease Society of America (IDSA)
1998-2000 Infectious Disease Society of America - Wisconsin Chapter
2002-2005 Drug Information Association

BIBLIOGRAPHY

Original Papers:

Bernstein B.M., Fass R.J., "Treatment of Osteomyelitis and Septic Arthritis with Cefamandole," The American Journal of The Medical Sciences, 284 (3):2-8, November-December,1982.

Murphy D.A., Bahr G.R., Kelly J.A., Bernstein B.M., and Morgan M., "A Needs Assessment Survey of HIV-infected Patients," Wisconsin Medical Journal, pp.291-295, June, 1992.

Gould John S., Erickson Scott J., Collier B.D., **Bernstein B.M.**, "Surgical Management of Ulcers, Soft Tissue Infections, and Osteomyelitis in the Diabetic Foot," Instructional Course Lecture

Series, American Academy of Orthopedic Surgeons, 42(11): 147-158, 1993.

Kelly J.A., Murphy D.A., Bahr G.R., Koob J.J., Morgan M.G., Kalichman S.C., Stevenson L.Y., Brasfield T.L., **Bernstein B.M.**, St. Lawrence J.S., "Factors Associated With Severity of Depression and High-Risk Sexual Behavior Among Persons Diagnosed With Human Immunodeficiency Virus (HIV) Infection," Health Psychology, 12(3): 215-219, 1993.

Kelly J.A., Murphy D.A., Bahr R.G., Kalichman S.C., Morgan M.G., Stevenson L.Y., Koob J.J., Brasfield T.L., **Bernstein B.M.**, "Outcome of Cognitive-Behavioral and Support Group Brief Therapies for Depressed, HIV Infected Persons," The American Journal of Psychiatry, 150(11):1679-1686, November, 1993.

Bernstein B.M., Gill Cox J., "Natural History and Therapy of Hepatitis B and C in Patients with HIV Disease," In P. Volberding and M. Jacobson (Eds.), AIDS Clinical Review 1993/1994, pp. 129-143, Marcel Dekker, Inc., San Francisco, CA., 1993.

Spruance S.L., Pavia A.T., Peterson D., Berry A., Pollard R., Patterson T., Frank I., Remick S.C., Thompson M., MacArthur R., Morey G.E. Jr., Ramirez-Ronda C.H., **Bernstein B.M.**, et. al., for the Bristol-Myers Squibb AI454-010 Study Group, "Didanosine Compared with Continuation of Zidovudine in HIV-infected Patients with Signs of Clinical Deterioration While Receiving Zidovudine," Annals of Internal Medicine, 120(5): 360-368, March, 1994.

Bernstein B.M., Flomenberg P., Letzer D., "Disseminated Cryptococcal Disease Complicating Steroid Therapy for Pneumocystis Carinii Pneumonia in a Patient with AIDS", Southern Medical Journal, 87(4): 537-538, April, 1994.

Findling J.W., Buggy B.P., Gilson I.H., Brummitt C.F., **Bernstein B.M.**, Raff H., "Longitudinal Evaluation of Adrenocortical Function in Patients Infected with the Human Immunodeficiency Virus", Journal of Clinical Endocrinology and Metabolism, 79(4):1091 - 1096, October, 1994

Bernstein, B.M., "The Common Cold". In John Noble (Second Edition), Textbook of Primary Care Medicine, pp. 1517-1522, Mosby-Year Book, Inc., St. Louis, MO., 1996.

Bernstein, B.M., Brennan, T. G., Horowitz, H. W., Mitsuyasu, R. T., Wilcox, C. M., "Managing Active HIV Disease". AIDS Primary Care Handbook/Patient Care, pp. 103-128, May, 1996

Bernstein, B.M., "The Importance of Viral Load Testing in a Clinical Setting", Wisconsin AIDS/HIV Update, October, 1996

Koller, E.A., Gilbert, C.L., Green, L., Mann, M., **Bernstein, B.**, "Thrombotic Events with Megestrol Acetate for AIDS Wasting", Nutrition: The International Journal of Applied and Basic Nutritional Sciences. 1998

Kempf, D.J., Isaacson, J.D., King, M.S., Brun, S.C., Xu, Y., Real, K., **Bernstein, B.M.**, et. al., "Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients, Journal of Virology, 75(16):7462-7469, Aug, 2001

Walmsley, S., **Bernstein, B.**, et al., "A Randomized, Double-Blind Study of Lopinavir/ritonavir, Stavudine, and Lamivudine versus Nelfinavir, Stavudine, and Lamivudine in Antiretroviral-Naïve, HIV-Infected Adults" New Eng J Med, 26(346): 2039-2046, Jun, 2002

Kempf, D., Isaacson, J., King, M., Brun, S., Sylte, J., Richards, B., **Bernstein, B.**, et al., "Analysis of

the Virologic Response with Respect to Baseline Viral Phenotype and Genotype in Protease-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy” Antiviral Therapy, 7(3): 165-174, Sep, 2002

Xavier Sáez-Llorens, MD, Avyi Violari, MD, Carl O. Deetz, BA, Richard A. Rode, PhD, Perry Gomez, FACP, Edward Handelsman, MD, Stephen Pelton, MD, Octavio Ramilo, MD, Pedro Cahn, MD, Ellen Chadwick, MD, Upton Allen, FRCPC, Stephen Arpadi, MD, Maria Mercedes Castrejón, MD, Renee S. Heuser, BS, Dale J. Kempf, PhD, Richard J. Bertz, PhD, Ann F. Hsu, PhD, **Barry Bernstein**, MD, Cheryl L. Renz, MD, and Eugene Sun, MD. “Forty-eight Week Evaluation of Lopinavir/ritonavir, a new protease inhibitor, in HIV-infected Children” Pediatric Infectious Disease Pediatr Inf Dis J. 2003;22:216-23.

Joseph J Eron, Judith Feinberg, Harold A Kessler, Harold W Horowitz, Malory D. Witt, Felix F Carpio, David A Wheeler, Peter Ruane, Donna Mildvan, Bienvenido G Yangco, Richard Bertz, **Barry Bernstein** et al. “Once-Daily Versus Twice-Daily Lopinavir/Ritonavir in Antiretroviral-Naïve HIV-Positive Patients: A 48 Week Randomized Clinical Trial” The Journal of Infectious Diseases 2004;189: 265-272

Martin S King, **Barry M Bernstein** et al. “Baseline HIV-1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir but not to Lopinavir/Ritonavir in Antiretroviral-Naïve Patients” The Journal of Infectious Diseases;2004:190

Dale J. Kempf, Jeffrey D. Isaacson, Martin S. King, Scott C. Brun, Jacquelyn Sylte, Bruce Richards, **Barry Bernstein** et al. “Analysis of the virologic response with respect to baseline viral genotype and phenotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy” Antiviral Therapy 2002;7:165-174

Dale J. Kempf, Martin S. King, Barry Bernstein, et al. “Incidence of Resistance in a Double-Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine” The Journal of Infectious Diseases 2004; 189:51–60

Sherie Masse, Xiaozhi Lu, Tatyana Dekhtyar, Liangjun Lu1, Gennadiy, Koev, Feng Gao, Hongmei Mo, Dale Kempf, **Barry Bernstein**, George J Hanna Akhteruzzaman Molla. “In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir” Antimicrobial Agents and Chemotherapy 2007; 51:3075–3080

Podzamczar D; King MS; Klein CE; Flexner C; Katlama C; Havlir DV; Letendre SL; Eron JJ; Brun SC; **Bernstein B**. “High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response” HIV Clinical Trials 2007; 8: 193-204

Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; **Bernstein B**; Hanna GJ. “Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen” Journal of Antimicrobial Chemotherapy 2007; 59: 957-63

Sarah Palmer, Frank Maldarelli, Ann Wiegand, **Barry Bernstein**, George J. Hanna, Scott C. Brun, Dale J. Kempf, John W. Mellors, John M. Coffin, and Martin S. King. “Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy” Proceedings of the National Academy of Sciences 2008;105: 3879–3884

D. William Cameron, Barbara A. da Silva, Jose R. Arribas, Robert A. Myers, Nicholas C. Bellos, Norbert Gilmore, Martin S. King, **Barry M. Bernstein**, Scott C. Brun, and George J. Hanna. “A 96-Week Comparison of Lopinavir- Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy” The Journal of Infectious Diseases 2008;198: 234-240

- Sibtain Rahim, Linda M. Fredrick, Barbara A. da Silva, **Barry Bernstein**, and Martin S. King. "Geographic and Temporal Trends of Transmitted HIV-1 Drug Resistance Among Antiretroviral-Naïve Subjects Screening for Two Clinical Trials in North America and Western Europe" HIV Clinical Trials 2009;10:94–103
- Gathe J; da Silva BA; Cohen DE; Loutfy MR; Podzamczar D; Rubio R; Gibbs S; Marsh T; Naylor C; Fredrick L; **Bernstein B**. "A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks" Journal of Acquired Immune Deficiency Syndrome 2009; 50: 474-81
- Campo RE; Da Silva BA; Cotte L; Gathe JC; Gazzard B; Hicks CB; Klein CE; Chiu YL; King MS; **Bernstein BM**. "Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine" AIDS Research and Human Retroviruses 2009; 25: 269-75
- Todd T. Brown, MD, PhD, Grace A. McComsey, MD, Martin S. King, PhD, Roula B. Qaqish, PharmD, **Barry M. Bernstein, MD**, and Barbara A. da Silva, MD. "Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen" Journal of Acquired Immune Deficiency Syndrome 2009; 51: 554-61
- Roberto Zajdenverg, MD, Thomas J. Podsadecki, MD, Sharlaa Badal-Faesen, MD, Jaime Andrade-Villanueva, MD, Joseph Gathe, MD, Horacio Mingrone, MD, Linda M. Fredrick, MS, Isabelle A. Gaultier, MS, W. Chris Woodward, DO, and **Barry M. Bernstein, MD** "Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1–Infected Subjects at 48 Weeks" Journal of Acquired Immune Deficiency 2010; 54: 143-151.
- Eric Lawitz, Fred Poordad, Kris V. Kowdley, Daniel E. Cohen, Thomas Podsadecki, Sara Siggelkow, Lois Larsen, Rajeev Menon, Gennadiy Koev, Rakesh Tripathi, Tami Pilot-Matias, **Barry Bernstein** "A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1" Journal of Hepatology 2013;59: 18-23
- Fred Poordad, M.D., Eric Lawitz, M.D., Kris V. Kowdley, M.D., Daniel E. Cohen, M.D., Thomas Podsadecki, M.D., Sara Siggelkow, R.N., Michele Heckaman, M.S., Lois Larsen, Ph.D., Rajeev Menon, Ph.D., Gennadiy Koev, Ph.D., Rakesh Tripathi, M.S., Tami Pilot-Matias, Ph.D., and **Barry Bernstein, M.D.** "Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C" New England Journal of Medicine 2013; 368:45-53
- Kris V. Kowdley, M.D., Eric Lawitz, M.D., Fred Poordad, M.D., Daniel E. Cohen, M.D., David R. Nelson, M.D., Stefan Zeuzem, M.D., Gregory T. Everson, M.D., Paul Kwo, M.D., Graham R. Foster, F.C.R.P., Mark S. Sulkowski, M.D., Wangang Xie, Ph.D., Tami Pilot-Matias, Ph.D., George Liossis, B.A., Lois Larsen, Ph.D., Amit Khatri, Ph.D., Thomas Podsadecki, M.D., and **Barry Bernstein, M.D.** "Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1" New England Journal of Medicine 2014; 370:222-232
- Jordan J. Feld, M.D., M.P.H., Kris V. Kowdley, M.D., Eoin Coakley, M.D., Samuel Sigal, M.D., David R. Nelson, M.D., Darrell Crawford, M.D., Ola Weiland, M.D., Humberto Aguilar, M.D., Junyuan Xiong, M.S., Tami Pilot-Matias, Ph.D., Barbara DaSilva-Tillmann, M.D., Lois Larsen, Ph.D., Thomas Podsadecki, M.D., and **Barry Bernstein, M.D.** "Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin" New England Journal of Medicine 2014; 370:1594-1603
- Stefan Zeuzem, M.D., Ira M. Jacobson, M.D., Tolga Baykal, M.D., Rui T. Marinho, M.D., Ph.D., Fred Poordad, M.D., Marc Bourlière, M.D., Mark S. Sulkowski, M.D., Heiner Wedemeyer, M.D., Edward Tam, M.D., Paul Desmond, M.D., Donald M. Jensen, M.D., Adrian M. Di Bisceglie,

M.D., Peter Varunok, M.D., Tarek Hassanein, M.D., Junyuan Xiong, M.S., Tami Pilot-Matias, Ph.D., Barbara DaSilva-Tillmann, M.D., Lois Larsen, Ph.D., Thomas Podsadecki, M.D., and **Barry Bernstein, M.D.** "Retreatment of HCV with ABT-450/r– Ombitasvir and Dasabuvir with Ribavirin" New England Journal of Medicine 2014; 370:1604-1614

Fred Poordad, M.D., Christophe Hezode, M.D., Roger Trinh, M.D., M.P.H., Kris V. Kowdley, M.D., Stefan Zeuzem, M.D., Kosh Agarwal, M.D., Mitchell L. Shiffman, M.D., Heiner Wedemeyer, M.D., Thomas Berg, M.D., Eric M. Yoshida, M.D., Xavier Forns, M.D., Sandra S. Lovell, Ph.D., Barbara Da Silva-Tillmann, M.D., Christine A. Collins, Ph.D., Andrew L. Campbell, M.D., Thomas Podsadecki, M.D., and **Barry Bernstein, M.D.** "ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis" New England Journal of Medicine 2014; 370: 1973-1982

Andreone, Pietro ; Colombo, Massimo G. ; Enejosa, Jeffrey V. ; Koksai, Iftihar ; Ferenci, Peter ; Maieron, Andreas ; Müllhaupt, Beat ; Horsmans, Yves ; Weiland, Ola ; Reesink, Henk W. ; Rodrigues, Lino ; Hu, Yiran B. ; Podsadecki, Thomas ; **Bernstein, Barry** "ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection" Gastroenterology, 2014, Vol.147, pp.359-365

Yi-Lin Chiu*, Martin S King, Cheri E Klein, Daniel Cohen, and **Barry Bernstein** "Trough Lopinavir Concentrations do not Predict Virologic Response to Lopinavir/Ritonavir-Based Three-Drug Regimens in Antiretroviral-Naïve Patients" Journal of Pharmacology & Clinical Toxicology 2014 2(1): 1022

Editorials, Letters to the Editor:

Bernstein B.M., "Metastatic Papillary Adenocarcinoma Simulatory Toxoplasmosis on CT in a Patient with AIDS," American Journal of Roentgenology, 159:676-677, September, 1992.

Flomenberg P., Balliet K., Bernstein B., et al, "High Specificity of Hepatitis C Second-Generation Enzyme Immunoassay in HIV-Infected Patients", Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 9:97-102,1995.

Abstracts:

Findling J.W., Buggy B.P., Gilson I.H., Brummitt C.F., Bernstein, B.M., "Subnormal Aldosterone Response to ACTH In Patients with the Acquired Immunodeficiency Syndrome (AIDS), " 1998ed on June 21, 1990 Atlanta, GA: Program of the 72nd Annual Meeting of the Endocrine Society p. 231, 1990.

Kelly J.A., Murphy D.A., Bahr G.R., Koob J.J., Bernstein B.M., Brasfield T.L., Kalichman S.D., Davis D.R., and Brumfield E., "Outcome of Cognitive Behavioral and Social Support Group Therapies for Persons with HIV Infection Seeking Psychological Assistance," Paper 1998ed to the Annual Meeting of the North American Society for Psychotherapy Research, Panama City, FL; November, 1991.

Siegel Frederick P., Chaisson R., Stern J., Bernstein B.M., Lamarca A., Matthew E., Havlik J., Scheibel S., Thompson M., Bianchine J., Denio L., Schoenfelder J., Souder D., Wolgemuth R., Viray R., Wynne B., and the Rifabutin Study Group. Long Island Jewish Medical Center, New Hyde Park NY, USA. "Clinical Manifestations of M. Avium Complex (MAC) Bacteremia in Patients with AIDS," VII International Conference on AIDS/III STD World Congress, Amsterdam, The

Netherlands (1998ed) July 19-24, 1992.

Cameron W.A., Sparti P., Pietroski N., Pearce D.D., Eron L., Sullam P., Conanthew T., Deresinski S., Bernstein B.M., "Rifabutin Prevents M. Avium Complex (MAC) Bacteremia in Patients with AIDS and CD4<200," The 32nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Anaheim, California (Submitted for 1998ation) October 11-14, 1992.

Kelly J.A., Murphy D.A., Bahr G.R., Kalichman S.C., Morgan M.G., Koob J.J., Stevenson L.Y., Bernstein B.M., and Brasfield T.L., "Outcomes of Brief Cognitive Behavioral and Support Group Interventions on Coping, Substance Use, and Continued High-Risk Sex Among Distressed Persons Diagnosed with HIV Infection," APHA 120th Annual Meeting, Washington, D.C. 1993.

Buggy B.P., Brummitt C.F., Gilson I.H., Bernstein B.M., Raff H., Findling J.W., "Longitudinal Evaluation of Adrenocortical Function in Patients with HIV-1 Infection", (No. 397) St. Luke's Medical Center, Milwaukee, WI, USA. - IXth International Conference on AIDS IVth STD World Congress, Berlin. 1994.

Murphy D.A., Kelly J.A., Bahr G.R., Stevenson L.Y., Kalichman S.C., Koob J.J., Morgan M.G., Brasfield T.L., and Bernstein B.M., "Comparison of Cognitive-Behavioral and Social Support Group Psychotherapies for HIV-Infected Persons," IX International Conference on AIDS, Berlin. June, 1993.

Brennan T., Bernstein B.M., Gessert C., "Innovations in Clinical Training, Support, and Evaluation", VII International Society for AIDS Education Conference, Chicago, IL, 1993.

Kherallah M., Flomenberg P., Bernstein B., Gotoff R., Letzer D., "The Impact of a Community Outbreak of Cryptosporidium on HIV Positive Patients," The 34th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Orlando, Florida; October 4-7, 1994. Abstract J4.

Andris D.A., Krzywda E. A., Bernstein B.M., Quebbeman E. J., "AIDS and Cryptosporidiosis: Benefit vs. Risk of Total Parenteral Nutrition (TPN)", The 35th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA; September 17-20, 1995. Abstract I42.

11. Bernstein, B.M., "Outbreak of Burkholderia Cepacia Colonization and Infection Related to Contaminated Oral Mouthwash", (Poster) The 34th Annual IDSA Meeting, New Orleans, LA. Sept. 18-20, 1996. Abstract 494

Brennan, T.B., Bernstein, B.M., O'Hair, K., "High Volume/Low Volume Partnerships: Designing Integrative Programs for HIV Experts and their Colleagues in Care", Fourth National AIDS Education and Training Centers Workshop, New Orleans, LA March 12-14, 1998

Skowron, G., Leoung, G., Johnson, D., Fisher, A., Hewitt, R., Bernstein, B., et al "The Nevirapine/Nelfinavir Database: Viral Load and CD4 Cell Count Response in 121 Patients in 9 US Clinical Practices", (Poster) 36th Annual Meeting of the Infectious Disease Society of America, Denver, CO. November 12-16, 1998

D. Kemp, H. Mo, S. Brun, A. Molla, B. Bernstein, et al. "Analysis of Virological Response to ABT-378/ritonavir (ABT-378/r) Therapy in PI Experienced Patients with Respect to Baseline Viral Phenotype and Genotype." (Abstract) 3rd International Workshop on Drug Resistance and Treatment

Strategies, San Diego. June 23-26, 1999.

- C. Benson, S. Brun, Y. Xu, K. Orth, S. Deeks, H. Kessler, R. Murphy, D. Wheeler, C. Hicks, J. Eron, J. Feinberg, R. Gulick, P. Sax, R. Stryker, S. Riddler, M. Thompson, M. King, C. Fields, A. Potthoff, B. Bernstein, et al. "ABT-378/ritonavir (ABT-378/r) in protease inhibitor experienced HIV infected patients: preliminary 24 weeks results." (Abstract 7) 3rd International Workshop on Drug Resistance and Treatment Strategies, San Diego. June 23-26, 1999.
- D. Kempf, Y. Xu, S. Brun, M. King, H. Mo, K. Real, B. Bernstein, et al "Baseline Genotypic and Phenotypic Do Not Predict Response to ABT-378/Ritonavir in PI-Experienced Patients at 24 and 48 Weeks." (Abstract) 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. January 30 – February 2, 2000.
- D. Kempf, S. Brun, R. Rode, J. Isaacson, M. King, Y Xu, A. Hsu, R. Granneman, Y. Lie, N. Hellman, B. Bernstein, E. Sun "Identification of Clinically Relevant Phenotypic and Genotypic Breakpoints for ABT-378/r in Multiple PI-experienced, NNRTI-naïve Patients." (Abstract 89) 4th International Workshop on HIV Drug Resistance and Treatment Strategies, Sitges, Spain. June 12-16, 2000.
- D. Kempf, J. Isaacson, M. King, S. Brun, Y. Xu, K. Real, Y. Lie, N. Hellmann, K. Hertogs, B. Larder, B. Bernstein, et al "Genotypic Correlates of Reduced In Vitro Susceptibility to ABT-378 in HIV Isolates from Patient Failing Protease Inhibitor Therapy." (Abstract) 4th International Workshop on HIV Drug Resistance & Treatment Strategies, Sitges, Spain. June 12-16, 2000.
- A. Molla, S. Brun, H. Mo, K. Real, J. Poddig, B. Bernstein, et al "Genotypic and Phenotypic Analysis of Viral Isolates from Subjects with Detectable Viral Load on Therapy with ABT-378/Ritonavir." (Abstract) 4th International Workshop on HIV Drug Resistance & Treatment Strategies, Sitges, Spain. June 12-16, 2000.
- A. Violari, B. Bernstein, et al "ABT-378/Ritonavir in HIV-Infected Children." (Abstract) The XIII International AIDS Conference, Durban, South Africa. July 9-14, 2000.
- A. Hsu, J. Isaacson, D. J. Kempf, M. King, R. Rode, W. Lam, S. Brun, B. Bernstein, et al "Trough Concentration-EC50 Relationship as a Predictor of Viral Response for ABT-378/ritonavir (ABT-378) in Treatment-Experienced Patients." (Poster Session 171) 40th ICAAC, Toronto, Canada, September 17-20, 2000.
- R. Carr, A. Andre, R. Bertz, A. Hsu, W. Lam, M. Chang, P. Chen, L. Williams, B. Bernstein, E. Sun "Concomitant Administration of ABT-378/ritonavir (ABT-378/r) Results in a Clinically Important Pharmacokinetic (PK) Interaction with Atorvastatin (ATO) but not Pravastatin (PRA). (Abstract) 40th ICAAC, Toronto, Canada. September 17-20, 2000.
- L. Gustavson, W. Lam, R. Bertz, A. Hsu, K. Rynkiewicz, Q. Ji, S. Ghosh, I. Facey, B. Bernstein, E. Sun "Assessment of the Bioequivalence and Food Effects for Liquid and Soft Elastic Capsule Co-Formulations of ABT-378/ritonavir (ABT-378/r) in Health Subjects." (Poster) 40th ICAAC, Toronto, Canada. September 17-20, 2000.
- S. Brun, D. Kempf, A. Molla, H. Mo, Y. Xu, K. Real, T. Marsh, J. Sylte, K. Hertogs, B. Larder, Y. Kie, N. Hellmann, W. Freimuth, B. Bernstein, et al "Analysis of Viral Isolates Following Viral Load Rebound on Therapy with ABT-378/r." (Oral Presentation 2112) 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. September 17-20, 2000.
- A. Hsu, R. Bertz, C. Renz, W. Lam, C. Deetz, S.M. Schweitzer, B. Bernstein, et al "Assessment of Pharmacokinetic Interactions Between Kaletra[™] (lopinavir/ritonavir or ABT-378/r) and Nevirapine in Pediatric Subjects." (Poster 440) 5th International Congress on Drug Therapy in HIV Infection, Glasgow, UK. October 22-26, 2000.
- S. Walmsley, A. Badley, G. Beal, W. Cameron, D. Johnson, M. Johnson, P. Ruane, R. Rubio, R. Stryker,

- M. King, P. Cernhous, J. Moseley, M. Opferman, M. Sattler, B. Bernstein, et al. "A Phase III, Randomized, Double-blind Trial of ABT-378/ritonavir (ABT-378/r) + Stavudine d4T/3TC Handout Accompanying the Oral Presentation: The M98-863 Study Group." 5th International Congress on Drug Therapy in HIV Infection, Glasgow, UK. October 22-26, 2000.
- M. Johnson, G. Beall, A. Badley, W. Cameron, D. Johnson, P. Ruane, R. Rubio, R. Stryker, S. Walmsley, M. King, P. Cernhous, J. Moseley, M. Opferman, M. Sattler, B. Bernstein, et al. "A Phase III, Randomized, Double-Blind Trial of Kaletra™ (ABT-378/r) + Stavudine (d4T) and Lamivudine (3TC) vs. Nelfinavir + d4T/3TC Handout Accompanying Oral Presentation: The M98-863 Group." 5th International Congress on Drug Therapy in HIV Infection, Glasgow, UK. October 22-26, 2000.
- D.J Kempf, J Issacson, M King, R Rode, S Brun, Y Xu, K. Real, A. Hsu, R. Granneman, B. Bernstein, E. Sun. "Interpretation of Phenotypic and Genotypic Resistance to Kaletra™ (ABT-378/ritonavir) in Protease Inhibitor Experienced Patients." (Poster F148-F149) 5th International Congress on Drug Therapy in HIV infection, Glasgow, UK. October 22-26, 2000.
- B. Bernstein, et al "Lack of Resistance to Kaletra (formerly known as ABT-378/r) Observed Through 24 Weeks of Therapy in Antiretroviral-Naïve Subjects." (Poster) 5th International Congress on Drug Therapy in HIV Infection, Glasgow, UK. October 22-26, 2000.
- B. Bertz, A. Hsu, W. Lam, L. Williams, C. Renz, M. Karol, S. Dutta, R. Carr, Y. Zhang, Q. Wang, S. Schweitzer, C. Foit, A. Andre, B. Bernstein, et al "Pharmacokinetic Interactions Between Kaletra™ (lopinavir/ritonavir or ABT-378/r) and Other Non-HIV Drugs." (Poster 438) 5th International Congress on Drug Therapy in HIV Infection, Glasgow, UK. October 22-26, 2000.
- J. Arribas, C. Barros, Gonzalez-Latroz, W. Cameron, R. Rubio, F. Altica, B. Clotet, M. King, P. Cernhous, J. Moseley, M. Sattler, E. Bauer, B. Bernstein, et al "Treatment of HIV+ Subjects Co-infected with Hepatitis B or C Safety and Efficacy Comparison of Kaletra™ (ABT-378/ritonavir) vs. Nelfinavir from a Phase III Blinded Randomized Clinical Trial." (Poster) 5th International Congress on Drug Therapy in HIV Infection, Glasgow, UK. October 22-26, 2000.
- M. King, B. Bernstein, et al "Comparison of Time to Achieve HIV RNA <400 copies/mL and <50 copies/mL in a Phase III Blinded Randomized Clinical Trial of ABT-378/r vs. NFV in ARV-Naïve Patients." (Abstract) Retrovirus 2001, Chicago, IL. February 2001.
- R. Reitmayer, R. Rode, B. Bernstein, et al. "Results from the Kaletra™ Early Access Program." (Poster) Retrovirus 2001, Chicago, IL. February 2001.
- R. Reitmayer, R. Rode, B. Bernstein, A. Meints, S. Brun, C. Kelly, E. Sun "Initial Efficacy Results from the KALETRA (formerly known as ABT-3/r) Early Access Program." (Abstract) Retrovirus 2001, Chicago, IL. February 2001.
- B. Bernstein, J. Moseley, D. Kemp, M. King, K. Gu, E. Bauer and E. Sun. "Absence of Resistance to Kaletra (ABT-378/r) Observed Through 48 Weeks of Therapy in Antiretroviral Naïve Subjects." (Abstract) Retrovirus 2001, Chicago, IL. February 2001.
- B. Bernstein, M. King, S. Brun P. Cernohous, A. Potthoff, F. Moseley, M. Sullivan, K. Grebner, and E. Sun. "Safety of Kaletra™: Data from Phase II and Phase III Clinical Trials." (Abstract) 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 2001
- D. Kempf, B. Bernstein, M. King, P. Cernohous, J. Moseley, K. Gu, E. Bauer, E. Sun. "Comparison of Genotypic Resistance over 60 Weeks of Therapy with Lopinavir/ritonavir (Kaletra™) or Nelfinavir plus d4T/3TC." (Abstract) 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 2001.
- P. Ruane, J. Mendonca, A. Timerman, P. Cernohous, E. Bauer, B. Bernstein, and E. Sun. "Kaletra™ vs. Nelfinavir in Antiretroviral-Naïve Subjects: Week 60 Comparison in a Phase III, Blinded, Randomized Clinical Trial." (Abstract) 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 2001.

- B. Bernstein, D. Kempf, M. King, J. Moseley, K. Gu, P. Cernohous, E. Bauer and E. Sun
“Comparison of the Emergence of Resistance in a Blinded Phase III Study with Kaletra ä (lopinavir/ritonavir) or Nelfinavir plus d4T/3TC from Week 24 Through Week 96. (Poster) 41st Annual ICAAC Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, December 2001
- J. Eron, B. Bernstein, M. King, et. al. “Once-Daily vs. Twice-Daily Kaletra (lopinavir/ritonavir) in Antiretroviral-Naïve HIV+ Patients: 48-Week Follow-up.” 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA. February 24 – 28, 2002
- M. King, B. Bernstein, P. Cernohous, J. Moseley, E. Bauer and E. Sun. “Impact of Baseline CD4 Cell Count and HIV RNA Level on Durability of Virologic Response Through 96 Weeks for Lopinavir/ritonavir (LPV/r) and Nelfinavir (NFV) In a Randomized Phase III Clinical Trial.” 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA. February 24 – 28, 2002
- J. Isaacson, D. Kempf, V. Calvez, I. Cohen-Codar, D. Descamps, E. Guillevic, B. Bernstein, E. Sun, JP. Chauvin and R. Rode. “Quantitative Estimate of the Effect of Individual Baseline Mutations in HIV Protease on the Virologic Response to Lopinavir/Ritonavir Therapy in Heavily Antiretroviral-Experienced Patients.” 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA. February 24 – 28, 2002
- R. Bertz, C. Foit, Y. L. Chiu, B. Bernstein, S. Boller, J.R. Owen, L. Williams, Q. Ji, C. Renz, A. Hsu, G. R. Granneman and E. Sun. “Multiple-Dose Kaletra (Lopinavir/ritonavir) Does Not Affect the Pharmacokinetics of the CYP2D6 Probe, Desipramine.” 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA. February 24 – 28, 2002
- R. Bertz, C. Foit, X. Ye, L. Manning, B. Bernstein, C. Renz, A. Hsu, M. King, G. R. Granneman and E. Sun. “Pharmacokinetics of Once Daily vs. Twice Daily Kaletra (Lopinavir/ritonavir) in HIV+ Subjects.” 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA. February 24 – 28, 2002
- D Kempf, M King, E Bauer, J Moseley, B Bernstein, S Brun, E Sun. “Comparative Incidence and Temporal Accumulation of PI and NRTI Resistance in HIV-Infected Subjects Receiving Lopinavir/ritonavir or Nelfinavir as Initial Therapy” 10th Conference on Retroviruses and Opportunistic Infections, Boston MA February 10-14, 2003
- J. Peng, R. Bertz, A. Hsu, J. Li, E. Ashbrenner, K. Grebner, J. Moseley, T. Reisch, J. Denissen, W. Cameron, B. Bernstein. “Evaluation of Single and Multiple Dose Pharmacokinetics of Ritonavir in Subjects with Mild or Moderate Hepatic Insufficiency” 4th Annual International Workshop on Clinical Pharmacology on HIV Therapy, March 27-19, 2003
- R. Bertz, Y-L. Chiu, C. Foit, P. Horn, D. Selness, B. Bernstein, M. Fath and D. Kempf. “ Estimation of Selective Pressure by Lopinavir/ritonavir (LPV/r) vs. Nelfinavir (NFV) by Examination of Terminal-Phase Pharmacokinetics (PK) at Steady-State” 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, Italy, April 1-3, 2004
- CE Klein, YL Chiu, B Bernstein, GJ Hanna, W Awni. “Predicted Lopinavir and Ritonavir Pharmacokinetics of High Dose Lopinavir/Ritonavir as the Tablet Formulation” 5th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal, April 20-22, 2006
- W Liu, CE Klein, K Marsh, L Hernandez, BM Bernstein, GJ Hanna. “Predicted Pharmacokinetics (PK)

of Lopinavir (LPV) after Multiple-Dose Administration of Lopinavir/Ritonavir (LPV/r) Tablet to Pediatric Patients” 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 12-16, 2006

CE Klein, Y Cai, YL Chiu, SJ Causemaker, TT Doan, TJ Podsadecki, BM Bernstein and GJ Hanna. “Pharmacokinetics of Lopinavir and Ritonavir after Multiple Dose Administration of Lopinavir/Ritonavir Tablet Co-administered with Efavirenz” 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 12-16, 2006

M King, S Palmer, A Wiegand, F Maldarelli, B Bernstein, D Kempf, GJ Hanna, J Mellors, J Coffin. “Low-Level Viremia Decays Over 7+ Years to a Residual Level Correlated with Baseline HIV-1 RNA” 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 28-28, 2007

A. Molla, L. Lu, M. King, R. Woods, T. Pilot-Matias, E. Lam, J. Whitcomb, B. Bernstein, G. Hanna, D. Kempf. “Selective Advantage of HIV Protease Mutations Associated With Resistance to Lopinavir” XVI International HIV Drug Resistance Workshop, Bridgetown, Barbados, June 12 – 16, 2007

S. Palmer, A. Wiegand, T. Miura, B. Block, F. Pereyra, F. Maldarelli, M. King, G. Hanna, B. Bernstein, J. Mellors, B. Walker, and J. Coffin. “Low-Level Viremia in HIV-1-Infected Patients Classified as “Elite Controllers” Compared to Patients on Suppressive” XVI International HIV Drug Resistance Workshop, Bridgetown, Barbados, June 12 – 16, 2007

S Rahim, LM Fredrick, B da Silva, B Bernstein, M King and GJ Hanna. “Geographic and Temporal Trends of Transmitted HIV-1 Drug Resistance Among Antiretroviral-Naïve Subjects Screening for Clinical Trials” XVI International HIV Drug Resistance Workshop, Bridgetown, Barbados, June 12 – 16, 2007

M Nijhuis, P Schipper, M King, B Bernstein, G Hanna and CAB Boucher. “Changes in HIV Gag and protease cannot explain persistent viremia in the majority of patients failing first line lopinavir/ritonavir therapy” XVI International HIV Drug Resistance Workshop, Bridgetown, Barbados, June 12 – 16, 2007

Klein CE, Xiong J, Ng J, Causemaker SJ, Li J, Chiu YL, Woulfe M, Da Silva B, Bernstein B. “A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Co-administered with NRTIs in Antiretroviral Naïve HIV-1 Infected Subjects” 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, LA. April 7-9, 2008

Gathe J, da Silva BA, Loutfy M, Podzamczar D, Rubio R, Gibbs S, Marsh T, Naylor C, Fredrick L, Bernstein B. “Study M05-730 Primary Efficacy Results at Week 48: Phase 3, Randomized, Open-Label Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naïve (ARV) HIV-1 Infected Subjects” 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA. February 3-6, 2008

Brown TT, McComsey GA, King M, Qaqish RB, Bernstein B, da Silva BA. “Bone Mineral Density (BMD) 96 Weeks after Antiretroviral Therapy (ART) Initiation: A Randomized Trial Comparing Efavirenz (EFV)-Based Therapy to a Lopinavir/ritonavir (LPV/r)-Containing Regimen with Simplification to LPV/r Monotherapy” 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA. February 3-6, 2008

Juki Ng, Cheri Klein, Junyuan Xiong, Yi-Lin Chiu, Thao Doan, Charlotte Rolle, Cynthia Holas, Richard Stryker, Barry Bernstein. “Lopinavir/ritonavir (LPV/r) 500/125 mg BID Plus Efavirenz Approximate the Pharmacokinetic Exposure of LPV/r 400/100 mg BID Administered Alone in Healthy Adult Subjects” 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA. February 3-6, 2008

Barbara da Silva, Daniel Cohen, Sara Gibbs, Christian Naylor, Mary Woulfe, Christal Marincic, Linda Fredrick, Barry Bernstein. “Comparable HIV-1 Viral Suppression and Immunologic Recovery of White and Non-White Antiretroviral-Naïve Subjects Taking Lopinavir/ritonavir (LPV/r) Tablets + Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) through 48 Weeks” XVII International AIDS Conference, Mexico City, Mexico. August 3-8, 2008

Barbara da Silva, Daniel Cohen, Sara Gibbs, Theresa Marsh, Danielle Grant, Jan Hairrell, Isabelle Gaultier, Linda Fredrick, Barry Bernstein. “Impact of Gender on Response to Lopinavir/ritonavir (LPV/r) Tablets Dosed QD or BID Administered with Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) in Antiretroviral-naïve (ARV) Subjects: Results from Study M05-730” XVII International AIDS Conference, Mexico City, Mexico. August 3-8, 2008

Yi-Lin Chiu, Cheri Enders Klein, Jianling Li, Linda Fredrick, Barbara da Silva, Barry Bernstein. “Trough Lopinavir Concentrations <1 µg/mL Are Not Associated with Virologic Failure in Antiretroviral-Naïve Patients Receiving a Lopinavir/ritonavir-Based 3-Drug Regimen” XVII International AIDS Conference, Mexico City, Mexico. August 3-8, 2008

J Ng, CE Klein, SJ Causemaker, J Xiong, YL Chiu, K Wikstrom, TT Doan, TJ Podsadecki, B Bernstein. “A Comparison of the Single Dose Bioavailability of a Ritonavir Tablet Formulation Relative to the Ritonavir Soft Gelatin Capsule in Healthy Adult Subjects” XVII International AIDS Conference, Mexico City, Mexico. August 3-8, 2008

BA da Silva, Y-L Chiu, J Li, P Noertersheuser, W Awni, C Klein, T Doan, B Bernstein. “Evaluation of the impact of lopinavir/ritonavir (LPV/r) and ritonavir (RTV) on PR interval: Results from a thorough QT study. 9th International Congress on Drug Therapy in HIV Infection Glasgow, UK. November 9-13, 2008

BA da Silva, Y-L Chiu, J Li, P Noertersheuser, W Awni, C Klein, T Doan, B Bernstein. “Metabolic Evaluation of Study M05-730 through Week (Wk) 48: Phase 3, Randomized, Open- Label Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naïve (ARV) HIV-1 Infected Subjects” 9th International Congress on Drug Therapy in HIV Infection Glasgow, UK. November 9-13, 2008

C Klein, J Ng, YL Chiu, PM Diderichsen, B da Silva, B Bernstein, W Awni. “Population Pharmacokinetic/Pharmacodynamic Analyses of Lopinavir and Ritonavir in Subjects Receiving the Tablet Formulation” 9th International Congress on Drug Therapy in HIV Infection Glasgow, UK. November 9-13, 2008

C Klein, YL Chiu, P Noertersheuser, W Awni, C Holas, T Doan, B da Silva, B Bernstein. “Evaluation of the Impact of Lopinavir/ritonavir (LPV/r) and Ritonavir (RTV) on QTcF: Results of a Thorough QT Study” 9th International Congress on Drug Therapy in HIV Infection Glasgow, UK. November 9-13, 2008

CE Klein, YL Chiu, W Awni, J Ng, Y Cui, J Morris, T Podsadecki, D Kim, B Bernstein. “The Effect of Food on Ritonavir Bioavailability Following Administration of Ritonavir 100 mg Film-Coated Tablet in Healthy Adult Subjects” 9th International Congress on Drug Therapy in HIV Infection Glasgow, UK. November 9-13, 2008

Rajeev Menon, Daniel Cohen, Adel Nada, Emily Olson Dumas, Yi-Lin Chiu, Thomas Podsadecki, Walid Awni, Barry Bernstein, Cheri Enders Klein. “Pharmacokinetics and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Single Ascending Doses in Healthy Adult Volunteers” 44th Annual Meeting of the European Association for the Study of the Liver (EASL), Copenhagen, Denmark, April 22-26, 2009

Rajeev Menon, Daniel Cohen, Adel Nada, Yi-Lin Chiu, Thomas Podsadecki, Walid Awni, Barry Bernstein, Cheri Klein. “Pharmacokinetics, Safety and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Multiple Ascending Doses and Effect of Co-Administration of Ketoconazole in Healthy Subjects” 44th Annual Meeting of the European Association for the Study of the Liver (EASL), Copenhagen, Denmark, April 22-26, 2009

Juan Gonzalez Garcia, Daniel Cohen, Margaret Johnson, Louis Sloan, Linda Fredrick, Christian Naylor, Barbara da Silva, Barry Bernstein. “Comparable Safety and Efficacy With Once-daily (QD) Versus Twice-daily (BID) Dosing of Lopinavir/ritonavir (LPV/r) Tablets With Emtricitabine (FTC) + Tenofovir DF (TDF) in Antiretroviral (ARV)-naïve, HIV-1-infected Subjects: 96-Week Results of the Randomized Trial M05-730” 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention Cape Town, South Africa July 19-22, 2009

R. Zajdenverg, S. Badal-Faesen, J. Andrade-Villanueva, J. Gathe, H. Mingrone, A. Hermes, I. Gaultier, L. Fredrick, W. Woodward, A. Lawal, T. Podsadecki, B. Bernstein. “Lopinavir/ritonavir (LPV/r) tablets administered once- (QD) or twice-daily (BID) with NRTIs in antiretroviral-experienced HIV-1 infected subjects: Results of a 48-week randomized trial (Study M06-802)” 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention Cape Town, South Africa July 19-22, 2009

A Lawal, T Podsadecki, L Fredrick, B Bernstein. “Metabolic Evaluation of Study M06-802 through Week 48: Phase 3, randomized, open-label, study of lopinavir/ritonavir (LPV/r) tablets once daily (QD) versus twice daily (BID), in antiretroviral (ARV)-experienced HIV-1 infected subjects” 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV Philadelphia, USA October 26–28, 2009

DE Cohen, BA da Silva, S Gibbs, J Hairrell, T Marsh, C Naylor, L Fredrick, B Bernstein. “Incidence of Gastrointestinal Adverse Events by Baseline CD4+ T cell Count in Antiretroviral-Naïve Subjects after Starting Lopinavir/Ritonavir (LPV/r)-based Therapy in Study M05-730” 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV Philadelphia, USA October 26–28, 2009

Daniel E. Cohen, Martin S. King, Christian T. Naylor, Theresa M. Marsh, Barbara A. da Silva, Barry M. Bernstein “Resistance Implications of 96 Weeks of Treatment with Once- (QD) or Twice- (BID) Daily Lopinavir/ritonavir (LPV/r) with Tenofovir DF (TDF) and Emtricitabine (FTC) in Antiretroviral (ARV)-naïve Subjects” 12th European AIDS Conference Cologne, Germany November 11-14, 2009

Martin S. King, Adebayo A. Lawal, Linda M. Fredrick, Richard A. Rode, Thomas J. Podsadecki, Barry M. Bernstein “Improved Treatment Compliance with Once-Daily (QD) Compared to Twice-Daily (BID) Lopinavir/ritonavir (LPV/r) in HIV-1-Infected, Antiretroviral-Experienced Subjects” 12th

European AIDS Conference Cologne, Germany November 11-14, 2009

Martin S. King, Adebayo A. Lawal, Linda M. Fredrick, Thomas J. Podsadecki, Barry M. Bernstein
“Impact of Baseline Resistance on Virologic Outcome with Once-Daily (QD) or Twice-Daily (BID)
Lopinavir/ritonavir (LPV/r) through 48 Weeks of Combination Antiretroviral Therapy in
Treatment-Experienced, HIV-1-Infected Subjects” 12th European AIDS Conference Cologne,
Germany November 11-14, 2009

Isabelle A. Gaultier, Linda M. Fredrick, Adebayo A. Lawal, William C. Woodward, Ashwaq E. Hermes,
Karmin Y. Robinson-Morgan, Thomas J. Podsadecki, Barry M. Bernstein “Simplified Antiretroviral
Therapy in Special Populations: Clinical Outcomes at Week 48 of Lopinavir/ritonavir (LPV/r) Tablet
Dosed Once Daily (QD) or Twice Daily (BID), Administered with ≥ 2 Nucleoside Reverse
Transcriptase Inhibitors (NRTIs) in Antiretroviral-experienced Subjects, Analyzed by Gender, Age,
Race, Ethnicity, and Hepatitis Co-infection Status (Study M06-802)” 12th European AIDS
Conference Cologne, Germany November 11-14, 2009

Eric Lawitz, Isabelle Gaultier, Fred Poordad, Edwin DeJesus, Kris V. Kowdley, Gladys Sepulveda,
Daniel Cohen, Rajeev Menon, Lois M. Larsen, Thomas Podsadecki, Barry Bernstein “4-Week
Virologic Response and Safety of ABT-450 Given with Low-dose Ritonavir (ABT-450/r) First As
3-Day Monotherapy then in Combination with Pegylated Interferon Alpha-2a and Ribavirin (SOC) in
Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects” 61st Annual Meeting of the American
Association for the Study of Liver Diseases: The Liver Meeting® Boston, MA October
29-November 2, 2010

Eric Lawitz, Isabelle Gaultier, Fred Poordad, Daniel Cohen, Rajeev Menon, Lois M. Larsen, Thomas
Podsadecki, Barry Bernstein “Initial Antiviral Activity of the HCV NS3 Protease Inhibitor ABT-450
When Given with Low-dose Ritonavir as 3-Day Monotherapy: Preliminary Results of Study
M11-602 in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects” 61st Annual Meeting of the
American Association for the Study of Liver Diseases: The Liver Meeting® Boston, MA October
29-November 2, 2010